ArticleJournal of virology2013
Resistance to two heterologous neurotropic oncolytic viruses, Semliki Forest virus and vaccinia virus, in experimental glioma.
Article in Journal of virology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 21 citations in OpenAlex.
- PKR induces TGF-β and limits oncolytic immune therapy.Journal for immunotherapy of cancer · 2023Article
- Review
- Insertion of the Type-I IFN Decoy Receptor B18R in a miRNA-Tagged Semliki Forest Virus Improves Oncolytic Capacity but Results in Neurotoxicity.Molecular therapy oncolytics · 2017Article
- Oncolytic Alphaviruses in Cancer Immunotherapy.Vaccines · 2017Review
- The importance of imaging strategies for pre-clinical and clinical in vivo distribution of oncolytic viruses.Oncolytic virotherapy · 2017Review
- MicroRNA-Attenuated Clone of Virulent Semliki Forest Virus Overcomes Antiviral Type I Interferon in Resistant Mouse CT-2A Glioma.Journal of virology · 2015Article
- Attenuated Semliki Forest virus for cancer treatment in dogs: safety assessment in two laboratory Beagles.BMC veterinary research · 2015Article
- Overcoming tumor resistance by heterologous adeno-poxvirus combination therapy.Molecular therapy oncolytics · 2015Article
- Clonal variation in interferon response determines the outcome of oncolytic virotherapy in mouse CT26 colon carcinoma model.Gene therapy · 2015Article
- Bacterial-mediated knockdown of tumor resistance to an oncolytic virus enhances therapy.Molecular therapy : the journal of the American Society of Gene Therapy · 2014Article
- Tumor Restrictions to Oncolytic Virus.Biomedicines · 2014Review
- Smac mimetics and innate immune stimuli synergize to promote tumor death.Nature biotechnology · 2014Article
- Sindbis viral vectors transiently deliver tumor-associated antigens to lymph nodes and elicit diversified antitumor CD8+ T-cell immunity.Molecular therapy : the journal of the American Society of Gene Therapy · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 4 institutions in 2 countries.
Funding
Abstract
Attenuated Semliki Forest virus (SFV) may be suitable for targeting malignant glioma due to its natural neurotropism, but its replication in brain tumor cells may be restricted by innate antiviral defenses. We attempted to facilitate SFV replication in glioma cells by combining it with vaccinia virus, which is capable of antagonizing such defenses. Surprisingly, we found parenchymal mouse brain tumors to be refractory to both viruses. Also, vaccinia virus appears to be sensitive to SFV-induced antiviral interference.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.